CERo Therapeutics Inc. (CERO)
NASDAQ: CERO
· Real-Time Price · USD
8.74
0.74 (9.25%)
At close: Aug 18, 2025, 2:57 PM
CERo Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q2 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Jun 30, 2021 |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | 288.16K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | n/a | -288.16K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -4.95M | -2.1M | -4.4M | -5.15M | -4.55M | -369.34K | -429.8K | -1.54M | -590.27K | -1.29M | -836.68K | -376.58K | -404.78K | -332.03K | -1K |
Interest Income | 850.00 | -4.42K | 4.42K | n/a | n/a | 20.09K | 121.52K | 59.42K | 16.00 | 2.48M | 320.48K | 37.11K | 17.27K | n/a | n/a |
Pretax Income | -5.11M | -2.11M | -4.23M | -2.45M | -2.3M | -258.35K | -308.28K | -1.39M | -481.71K | 276.02K | 144.97K | -111.57K | -378K | -331.42K | -1K |
Net Income | -5.11M | -2.11M | -4.23M | -2.45M | -2.3M | -282.76K | -334.03K | -2.09M | -2.44M | -262.68K | 84.5K | -111.57K | -378K | -314.55K | -1K |
Selling & General & Admin | 2.2M | 1.17M | 2.63M | 2.43M | 3.29M | 374.59K | 430.9K | 1.52M | 566.57K | 1.37M | 786.68K | 326.58K | 354.78K | 251.71K | 1K |
Research & Development | 2.91M | 1.21M | 1.77M | 2.71M | 1.38M | n/a | n/a | 1.19M | 1.8M | n/a | n/a | n/a | n/a | n/a | n/a |
Other Expenses | -156.25K | n/a | n/a | n/a | -403.89K | -5.25K | 1.1K | -22.7K | -23.7K | 85.95K | -50K | -50K | -50K | -80.32K | n/a |
Operating Expenses | 4.95M | 2.38M | 4.4M | 5.15M | 4.26M | 369.34K | 429.8K | 1.54M | 590.27K | 1.29M | 836.68K | 376.58K | 404.78K | 332.03K | 1K |
Interest Expense | n/a | -26.61K | n/a | 16.98K | 9.63K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | 403.89K | n/a | n/a | 300.22K | -71.78K | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 4.95M | 2.97M | 4.4M | 5.15M | 4.55M | 369.34K | 429.8K | 1.54M | 590.27K | 1.29M | 836.68K | 376.58K | 404.78K | 332.03K | 1K |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | 24.41K | 25.75K | 44.66K | -273.58K | 538.7K | 60.46K | n/a | n/a | -16.87K | n/a |
Shares Outstanding (Basic) | 1.71M | 1.21M | 248.37K | 80.99K | 73.53K | 2.92K | 45.34K | 45.31K | 45.29K | 33.84K | 114.9K | 114.9K | 114.9K | 114.9K | 116.97K |
Shares Outstanding (Diluted) | 1.71M | 1.21M | 248.37K | 80.99K | 73.53K | 2.92K | 45.34K | 45.31K | 45.29K | 33.84K | 114.9K | 114.9K | 114.9K | 114.9K | 116.97K |
EPS (Basic) | -3.18 | 0.56 | -17.02 | -30.23 | -31.27 | -432.91 | -29.76 | -46.17 | -53.83 | -7.76 | 0.74 | -0.97 | -3.29 | -2.74 | -0.01 |
EPS (Diluted) | -3.18 | 0.56 | -17.02 | -30.23 | -31.27 | -432.91 | -29.76 | -46.17 | -53.83 | -7.76 | 0.00 | -0.00 | -3.29 | -2.74 | -0.01 |
EBITDA | -4.84M | -2.72M | -4.4M | -2.43M | -4.44M | -836.42K | -429.8K | -2.3M | -2.32M | n/a | n/a | -376.58K | -404.78K | -332.03K | n/a |
EBIT | -5.11M | 11.39M | -4.4M | -2.43M | -4.55M | -1.12M | -429.8K | -2.41M | -2.44M | -1.29M | -836.68K | -376.58K | -378K | -331.42K | -1K |
Depreciation & Amortization | 269.48K | -581.41K | n/a | n/a | 288.16K | 284.75K | 429.8K | 277.45K | 273.58K | 1.29M | 836.68K | n/a | n/a | n/a | 1K |